Integra LifeSciences Reports Third Quarter 2026 Financial Results – Ortho Spine News

Integra LifeSciences (IART) reported Q3 2026 revenues of $411.2M, up 2.3%. GAAP EPS was $0.19, adjusted EPS $0.59. The company cited $7M revenue impact from flood damage and softer Tissue Reconstruction results. Full-year guidance remains unchanged at $1.634B-$1.654B revenue and $2.30-$2.40 adjusted EPS. Post-quarter, IART completed a $2.1B debt refinancing.

Original reporting
Published Oct 21, 2026, 7:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra LifeSciences Reports Third Quarter 2026 Financial Results – Ortho Spine News — source image
Decision brief

The 30-second read

$IARTNeutralHigh
01

Why it matters

The Q3 earnings beat and $2.1 B refinancing provide fresh data for valuation models; guidance remains flat, suggesting limited upside beyond the earnings surprise.

02

Market read

First‑report earnings and financing news deliver actionable information for traders focused on med‑tech equities.

03

What to watch

Potential flood‑related disruptions at the Cincinnati facility may recur, and tissue‑reconstruction segment showed revenue decline.

Relevance 8/10Novelty 8/10Timing: immediate today

Background

Integra LifeSciences (IART) is a Nasdaq‑listed medical‑technology company providing specialty surgical and tissue‑reconstruction products.

Company-level read

Ticker impact

$IARTNeutralHigh confidence
Context

Integra LifeSciences reported Q3 2026 results, posted GAAP EPS $0.19, adjusted EPS $0.59, and announced a $2.1 billion debt refinancing with updated guidance.

Expected impact

moderate upside as market prices in stronger cash flow and refined leverage profile

Evidence & confidence

Positive earnings surprise and a large refinancing tranche signal financial flexibility, but mixed revenue growth and higher interest costs temper enthusiasm.

Market effects

Medical‑technology sector may see slight uplift from Integra's improved leverage and cash flow trends.

U.S. healthcare equities could experience modest buying pressure.

Limited to U.S. and global med‑tech investors; no broad macro effect.

Counterpoint

Higher interest expense from the new notes could pressure margins, leading to a muted or negative reaction.

Key entities

  • Stuart Essig

    Chairman and CEO of Integra LifeSciences, quoted on results and outlook.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.